Literature DB >> 8350639

Quantification of human plasma apolipoproteins C-I, C-II, and C-III by radioimmunoassays.

N D Bren1, A Rastogi, B A Kottke.   

Abstract

We have developed radioimmunoassays for the quantification of apolipoproteins (apo) C-I, C-II, and C-III in human plasma. The apo C proteins were isolated from very low-density lipoproteins of patients with hypertriglyceridemia, fractionated on a Sephacryl column, and purified by diethylaminoethyl cellulose anion-exchange chromatography followed by reverse-phase fast protein liquid chromatography. The assays were sensitive, specific, and reproducible, and the standards demonstrated parallel immunoreactivity with plasma samples. Patients with hypertriglyceridemia (triglyceride level more than 2,200 mg/liter)--14 patients with diabetes and 12 with type V hyperlipoproteinemia--were compared with age- and sex-matched control subjects. In comparison with the control groups, levels of apoproteins C-I, C-II, and C-III were significantly increased in both disease groups, but the ratios of the C peptides to triglycerides were significantly lower, an indication of a relative deficiency of C apoproteins in hypertriglyceridemic states. Independent radioimmunoassays for each of the C apolipoproteins would help to study their individual roles in triglyceride-rich lipoprotein metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8350639     DOI: 10.1016/s0025-6196(12)60601-6

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  3 in total

1.  Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes.

Authors:  Lisa Juntti-Berggren; Essam Refai; Ioulia Appelskog; Mats Andersson; Gabriela Imreh; Nancy Dekki; Sabine Uhles; Lina Yu; William J Griffiths; Sergei Zaitsev; Ingo Leibiger; Shao-Nian Yang; Gunilla Olivecrona; Hans Jörnvall; Per-Olof Berggren
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

Review 2.  Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle.

Authors:  Ismael Valladolid-Acebes; Per-Olof Berggren; Lisa Juntti-Berggren
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

3.  Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.

Authors:  Michelle Hilbert; Peter Kuzman; Wolf C Mueller; Jürgen Meixensberger; Ulf Nestler
Journal:  Sci Rep       Date:  2022-10-10       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.